Effects of postoperative osteoporosis treatment on subsequent fracture and the 5-year survival rates after hemiarthroplasty for hip fracture

ArticleAçık Erişim

Özet

Summary: According to the literature, only 20–30% of patients are screened for osteoporosis after a hip fracture. Osteoporosis treatment may have a potential protective effect on the 5-year mortality rate. Our results demonstrated that 5-year survival is higher in patients who received osteoporosis treatment after hemiarthroplasty for hip fracture compared with those who did not. Purpose: This study aims to investigate the status of osteoporosis treatment in patients who underwent hemiarthroplasty for an osteoporotic hip fracture and to compare subsequent fractures and the 5-year survival rates of these patients with those who did not receive the osteoporosis treatment. Methods: Patients > 65 years of age who underwent hemiarthroplasty for an osteoporotic hip fracture were included in this retrospective multicenter study. Patients who died within 12 months postoperative, who were lost to follow-up, and those with malignancy and secondary osteoporosis were excluded. Group I comprised patients who had no postoperative osteoporosis screening and treatment, and Group II comprised those who received the screening and treatment. Results: A total of 460 of 562 patients (82%) did not receive osteoporosis treatment after hip fracture. No significant difference was observed between the groups in terms of subsequent fracture numbers and fracture sites (p = 0.296 and 0.240, respectively). Mean 5-year survival rate was significantly higher in Group II (p = 0.002). Conclusions: According to our results, elderly patients who underwent hemiarthroplasty for an osteoporotic hip fracture were not commonly screened or treated for osteoporosis. Our results demonstrated no significant difference between the groups in terms of subsequent fracture. However, we observed a significant high 5-year survival rate among patients who received the osteoporosis treatment. © 2019, International Osteoporosis Foundation and National Osteoporosis Foundation.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13661Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s11657-019-0657-3Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCobden, Adem
dc.contributor.authorCobden, Serap Bulut
dc.contributor.authorCamurcu, Yalkin
dc.contributor.authorUcpunar, Hanifi
dc.contributor.authorDuman, Serda
dc.contributor.authorSofu, Hakan
dc.date.accessioned2026-10-18T20:28:29.691591316Z
dc.date.available2026-10-18T20:28:29.691591316Z
dc.date.issued2019
dc.description.abstractSummary: According to the literature, only 20–30% of patients are screened for osteoporosis after a hip fracture. Osteoporosis treatment may have a potential protective effect on the 5-year mortality rate. Our results demonstrated that 5-year survival is higher in patients who received osteoporosis treatment after hemiarthroplasty for hip fracture compared with those who did not. Purpose: This study aims to investigate the status of osteoporosis treatment in patients who underwent hemiarthroplasty for an osteoporotic hip fracture and to compare subsequent fractures and the 5-year survival rates of these patients with those who did not receive the osteoporosis treatment. Methods: Patients > 65 years of age who underwent hemiarthroplasty for an osteoporotic hip fracture were included in this retrospective multicenter study. Patients who died within 12 months postoperative, who were lost to follow-up, and those with malignancy and secondary osteoporosis were excluded. Group I comprised patients who had no postoperative osteoporosis screening and treatment, and Group II comprised those who received the screening and treatment. Results: A total of 460 of 562 patients (82%) did not receive osteoporosis treatment after hip fracture. No significant difference was observed between the groups in terms of subsequent fracture numbers and fracture sites (p = 0.296 and 0.240, respectively). Mean 5-year survival rate was significantly higher in Group II (p = 0.002). Conclusions: According to our results, elderly patients who underwent hemiarthroplasty for an osteoporotic hip fracture were not commonly screened or treated for osteoporosis. Our results demonstrated no significant difference between the groups in terms of subsequent fracture. However, we observed a significant high 5-year survival rate among patients who received the osteoporosis treatment. © 2019, International Osteoporosis Foundation and National Osteoporosis Foundation.
dc.identifier.doi10.1007/s11657-019-0657-3
dc.identifier.eissn1862-3514
dc.identifier.issn1862-3522
dc.identifier.issue1
dc.identifier.pmid31628566
dc.identifier.scopus2-s2.0-85073552386
dc.identifier.startpage100
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13661
dc.identifier.volume14
dc.identifier.wosWOS:000491439300001
dc.language.isoen
dc.publisherSpringer London
dc.relation.ispartofArchives of Osteoporosis
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHemiarthroplasty
dc.subjectHip fracture
dc.subjectMortality
dc.subjectOsteoporosis
dc.subjectSurvival
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectBone Density Conservation Agents
dc.subjectDiphosphonates
dc.subjectFemale
dc.subjectHip Fractures
dc.subjectHumans
dc.subjectMale
dc.subjectOsteoporotic Fractures
dc.subjectPostoperative Complications
dc.subjectPostoperative Period
dc.subjectRecurrence
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.subjectTurkey
dc.subjectalendronic acid
dc.subjectcalcium
dc.subjectdenosumab
dc.subjectibandronic acid
dc.subjectstrontium ranelate
dc.subjectvitamin D
dc.subjectbisphosphonic acid derivative
dc.subjectbone density conservation agent
dc.subjectArticle
dc.subjectcomparative study
dc.titleEffects of postoperative osteoporosis treatment on subsequent fracture and the 5-year survival rates after hemiarthroplasty for hip fracture
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus10
rdl.citation.wos11
rdl.departmentDepartment of Orthopaedics and Traumatology, Erzincan Binali Yildirim University Faculty of Medicine, Basbaglar Mahallesi, 24100, Erzincan, Turkey. yalkin.camurcu@gmail.com. | Department of Orthopaedics and Traumatology, Erzincan Binali Yildirim University Faculty of Medicine, Basbaglar Mahallesi, 24100, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)